<DOC>
	<DOCNO>NCT02292654</DOCNO>
	<brief_summary>Primary Objective : To evaluate safety tolerability olipudase alfa administer intravenously pediatric patient every 2 week 52 week . Secondary Objective : To characterize pharmacokinetic profile evaluate pharmacodynamics exploratory efficacy olipudase alfa administer intravenously pediatric patient every 2 week 52 week .</brief_summary>
	<brief_title>Safety , Tolerability , PK , Efficacy Evaluation Repeat Ascending Doses Olipudase Alfa Pediatric Patients &lt; 18 Years Age With Acid Sphingomyelinase Deficiency</brief_title>
	<detailed_description>The maximum study duration per patient approximately 18 month ( screen period : 60 day ; treatment period : 64 week ; post-treatment period : 37 day , applicable patient enrolls long term extension treatment trial ) .</detailed_description>
	<mesh_term>Niemann-Pick Disease , Type A</mesh_term>
	<mesh_term>Niemann-Pick Diseases</mesh_term>
	<mesh_term>Niemann-Pick Disease , Type C</mesh_term>
	<mesh_term>Lipidoses</mesh_term>
	<criteria>Inclusion criterion : The patient and/or patient 's parent ( ) /legal guardian ( ) must provide write informed assent/consent prior protocolrelated procedure perform . The patient age 0 &lt; 18 year age date inform assent/consent . The patient document deficiency acid sphingomyelinase measure peripheral leukocyte , cultured fibroblast , lymphocyte . The patient spleen volume ≥5 multiples normal ( MN ) measure magnetic resonance imaging ( MRI ) ; patient partial splenectomy allow procedure perform ≥1 year screen residual spleen volume ≥5 MN . The patient 's height 1 Zscore low . A negative serum pregnancy test female patient childbearing potential . Female patient childbearing potential male patient must willing practice true abstinence line prefer usual lifestyle , use 2 acceptable effective method contraception . Exclusion criterion : The patient receive investigational drug within 30 day study enrollment . The patient follow medical condition : An active , serious , intercurrent illness . Active hepatitis B hepatitis C infection . Infection human immunodeficiency virus ( HIV ) . Cirrhosis ( determine clinical evaluation ) . Significant cardiac disease ( eg , clinically significant arrhythmia , moderate severe pulmonary hypertension valvular dysfunction , &lt; 40 % leave ventricular ejection fraction echocardiogram ) . Malignancy diagnose within previous 5 year ( except basal cell carcinoma ) . Any extenuate circumstance significantly interfere study compliance , include prescribed evaluation followup activity . The patient acute rapidly progressive neurological abnormality . The patient homozygous SMPD1 gene mutation R496L , L302P , fs330 combination 3 mutation . The patient delay gross motor skill . The patient major organ transplant ( eg , bone marrow , liver ) . The patient require use invasive ventilatory support . The patient require use noninvasive ventilatory support awake &gt; 12 hour day . The patient , investigator 's opinion , unable adhere requirement study . The patient platelet count &lt; 60 × 10^3/µL ( base average 2 screen sample obtain 24 hour apart ) . The patient alanine aminotransferase aspartate aminotransferase &gt; 250 IU/L total bilirubin &gt; 1.5 mg/dL . The patient international normalize ratio ( INR ) &gt; 1.5 The patient unwilling unable abstain ingest alcohol day 3 day infusion olipudase alfa treatment period . Measuring alcohol concentration blood require . The patient schedule study inpatient hospitalization include elective surgery . The patient require medication ( ) may decrease olipudase alfa activity ( eg , fluoxetine , chlorpromazine ; tricyclic antidepressant [ eg , imipramine , desipramine ] ) . The patient breastfeeding . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>